FAQ
Questions and answers.
Short, honest answers.
What we do
What does Cytogent do?
Cytogent has built an experimental intelligence layer for resistant cancer. It helps oncology drug teams choose which combination experiments to run next, run them with laboratory partners, and update the plan from the results. It is delivered as a managed service: Decision-as-a-Service.
Is the platform available today?
Yes. The platform is built, and we are ready to start pilots with oncology asset teams and to partner with model laboratories. We have not published any client results yet.
Why start with osimertinib resistance?
Resistance after osimertinib in EGFR-mutant lung cancer is well described and varied, which makes it a demanding first test. It is a starting R&D focus, not a patient population we treat.
Proof and boundaries
Is Cytogent a diagnostic or a treatment tool?
No. It is not intended as a clinical diagnostic or as a tool to select treatment for any individual patient. Its intended use is preclinical and translational experiment selection for drug developers.
Does it replace wet-lab scientists?
No. Predictions are hypotheses; experiments decide. The aim is to help scientists spend scarce lab time and samples on the experiments most likely to teach them something.
How will you know if it works?
By measuring it. Our north-star aim is independently confirmed, decision-relevant findings per experimental budget. Each pilot compares loop-selected batches with how the team would otherwise choose, and we treat the calibration of uncertainty estimates as something to validate, not assume.
Working together
What does a pilot look like?
One candidate, one resistance question, one decision. A pilot includes a decision brief, a ranked batch, an uncertainty map, lab coordination, quality-checked results, independent confirmation, an executive package and an audit trail.
Who are your laboratory partners?
We do not name partners until agreements are in place and they have agreed to be named. Laboratories interested in working with us can read how we qualify partners.
How is my data handled?
Each project’s data is kept separate, behind explicit permission gates, with an audit trail. Project data is handled only under a written agreement.
Can I send data or compound structures through the website?
Please don’t. The site has no forms. In a first message, leave out patient-identifiable health data and confidential chemical structures; we will agree how to share data if a project goes ahead.
For patients and the public
Can you tell me which treatment I should have?
No. We cannot give medical advice, and our work is not intended for choosing anyone’s treatment. Please talk to your doctor or care team about your own care.
Why do cancer drugs stop working?
A tumour is made of many cells. A drug may stop most of them, but a few can survive by changing the drug’s target, switching to another growth signal, or changing type. When they grow back, the drug may work less well.
